Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3102 ARTÍCULOS , VIENDO DEL 2476 AL 2490

Role for antibodies in altering behavior and movement

Libbey JE, Fujinami RS.

Autism Res. 2010 Aug;3(4):147-52. doi: 10.1002/aur.144.

Definition and classification of hyperkinetic movements in childhood

Sanger TD, Chen D, Fehlings DL, Hallett M, Lang AE, Mink JW, Singer HS, Alter K, Ben-Pazi H, Butler EE, Chen R, Collins A, Dayanidhi S, Forssberg H, Fowler E, Gilbert DL, Gorman SL, Gormley ME Jr, Jinnah HA, Kornblau B, Krosschell KJ, Lehman RK, MacKinnon C, Malanga CJ, Mesterman R, Michaels MB, Pearson TS, Rose J, Russman BS, Sternad D, Swoboda KJ, Valero-Cuevas F.

Mov Disord. 2010 Aug 15;25(11):1538-49. doi: 10.1002/mds.23088.

Huntington's disease

Novak MJ, Tabrizi SJ.

BMJ. 2010 Jun 30;340:c3109. doi: 10.1136/bmj.c3109.

Hypothalamic and neuroendocrine changes in Huntington's disease

Hult S, Schultz K, Soylu R, Petersén A.

Curr Drug Targets. 2010 Oct;11(10):1237-49. doi: 10.2174/1389450111007011237.

Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice

Dowie MJ, Howard ML, Nicholson LF, Faull RL, Hannan AJ, Glass M.

Neuroscience. 2010 Sep 29;170(1):324-36. doi: 10.1016/j.neuroscience.2010.06.056. Epub 2010 Jul 1.

High insulinlike growth factor I is associated with cognitive decline in Huntington disease

Saleh N, Moutereau S, Azulay JP, Verny C, Simonin C, Tranchant C, El Hawajri N, Bachoud-Lévi AC, Maison P; Huntington French Speaking Group.

Neurology. 2010 Jul 6;75(1):57-63. doi: 10.1212/WNL.0b013e3181e62076.

Before chorea: pre-Huntington mild cognitive impairment

Lichter DG, Hershey LA.

Neurology. 2010 Aug 10;75(6):490-1. doi: 10.1212/WNL.0b013e3181ec805b. Epub 2010 Jul 7.

Brain structure in movement disorders: a neuroimaging perspective

Draganski B, Bhatia KP.

Curr Opin Neurol. 2010 Aug;23(4):413-9. doi: 10.1097/WCO.0b013e32833bc59c.

Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease

Lundin A, Dietrichs E, Haghighi S, Göller ML, Heiberg A, Loutfi G, Widner H, Wiktorin K, Wiklund L, Svenningsson A, Sonesson C, Waters N, Waters S, Tedroff J.

Clin Neuropharmacol. 2010 Sep-Oct;33(5):260-4. doi: 10.1097/WNF.0b013e3181ebb285.

Differential diagnosis of dystonia

Elia AE, Lalli S, Albanese A.

Eur J Neurol. 2010 Jul;17 Suppl 1:1-8. doi: 10.1111/j.1468-1331.2010.03052.x.

Movement disorders associated with moyamoya disease: a report of 4 new cases and a review of literatures

Baik JS, Lee MS.

Mov Disord. 2010 Jul 30;25(10):1482-6. doi: 10.1002/mds.23130.

Towards the treatment of polyglutamine diseases: the modulatory role of protein context

Robertson AL, Bottomley SP.

Curr Med Chem. 2010;17(27):3058-68. doi: 10.2174/092986710791959800.

Control of RNA silencing and localization by endolysosomes

Gibbings D, Voinnet O.

Trends Cell Biol. 2010 Aug;20(8):491-501. doi: 10.1016/j.tcb.2010.06.001. Epub 2010 Jul 13.

Group I metabotropic glutamate receptor signalling and its implication in neurological disease

Ribeiro FM, Paquet M, Cregan SP, Ferguson SS.

CNS Neurol Disord Drug Targets. 2010 Nov;9(5):574-95. doi: 10.2174/187152710793361612.

Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders

Bisogno T, Di Marzo V.

CNS Neurol Disord Drug Targets. 2010 Nov;9(5):564-73. doi: 10.2174/187152710793361568.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias